News Category
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, with European approval and an FDA-...
Med-X is expanding its natural pest-control brand Nature-Cide and has secured OMRI certification, positioning itself for growth as it prepares for a p...
Telomir Pharmaceuticals' Telomir-Zn inhibits osteosarcoma growth in human and canine cell lines, opening a potential dual veterinary-human development...
Quantum BioPharma has received FDA clearance of its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis ...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA could strengthen regulatory confidence and h...
Tevard Biosciences announced preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has broadened its functionalized lipid-based delivery capabilities to help researchers overcome stability, targeting, and controlled ...
Creative Biolabs has broadened its single-cell and single-nucleus RNA sequencing and multi-omics offerings to help researchers overcome complex sample...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering a new ...
GeoVax Labs appeals its Nasdaq delisting determination, staying suspension pending an October hearing, while reaffirming its commitment to advancing i...
Regentis Biomaterials reported first half 2026 results, highlighting progress in its Phase III GelrinC trial, a 400% yield increase in manufacturing, ...
Quantum BioPharma's FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class myelin-protecting and rebuilding candidate, could transform ...
TransCode Therapeutics has named John Tattory as interim CFO following the retirement of Tom Fitzgerald, bringing extensive financial leadership to th...
VERAXA Biotech's appointment of Dr. Christoph Erkel as Chief Scientific Officer signals a strategic push to advance its conditionally active BiTAC® T-...
Quantum BioPharma receives FDA clearance to launch a phase 2 trial of Lucid-MS, the first drug designed to shield and rebuild myelin in multiple scler...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, has received FDA clearance to proceed to a Phase 2 trial in multiple scler...
Quantum BioPharma's Lucid-MS becomes the first drug designed to protect and rebuild myelin to enter human testing for multiple sclerosis, potentially ...
Helus Pharma CEO Michael Halstead's upcoming fireside chat at the Morgan Stanley Global Healthcare Conference highlights the company's late-stage deve...
Onco-Innovations' CMO discusses the potential of ONC010, a novel PNKP inhibitor with dual selectivity mechanisms, as it advances toward first-in-human...
Quantum BioPharma's FDA clearance of its IND application for Lucid-MS marks a critical step toward a Phase 2 trial in multiple sclerosis, potentially ...
American Fusion's Texatron program has entered active testing with record-high confinement pressures, signaling a critical step toward commercial fusi...
Kairos Pharma's CEO will present at the H.C. Wainwright conference, underscoring the company's progress in overcoming cancer drug resistance with its ...
Nutriband's CEO attendance at the Nasdaq LaB Biotech Summit underscores the company's strategic focus on transdermal pharmaceuticals and abuse-deterre...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its progress in developing SPC-15, a nose-to-brain drug delivery sy...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial highlights a novel approach to MS that could protect and repair myelin, not just suppress...
Quantum BioPharma's Lucid-MS has received FDA clearance to begin a Phase 2 clinical trial, a rare milestone for a micro-cap biotech that could validat...
Helus Pharma's CEO will discuss the company's lead candidates and strategic direction at the H.C. Wainwright conference, underscoring its potential to...
GeoVax endorses the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to bolster diversified supply and preparedness.
Voyageur Pharmaceuticals receives a $1 million milestone payment from Bayer after proving its proprietary iodine extraction process, advancing a proje...
Greenland Mines announces Q4 biotech spin-off and board changes as it focuses on rare earths, with the Sarfartoq project's initial assessment showing ...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to enhance its financial leadership and support its oncology pipeline de...
Scinai Immunotherapeutics strategically pivots its R&D to its NanoAb platform and CDMO services after terminating its PC111 license, aiming to optimiz...
Onco-Innovations advances its oncology pipeline with manufacturing and IND-enabling progress, strategic partnerships, and new funding, positioning ONC...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in Phase 2 trials marks a potential paradigm shift in MS tre...
OS Animal Health, a subsidiary of OS Therapies, is featured at the Moody Capital conference, highlighting its progress in developing OST-HER2 for cani...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class myelin repair candidate, marks a potential paradigm shift in treat...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Pan African Clinical Trials Registry, marking a critical step in ...
Greenland Mines (NASDAQ: GRML) announced its Q4 2026 biotech spin-off and completed the Sarfartoq acquisition, positioning itself as a focused rare ea...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS marks a critical step toward a novel treatment that targets demyelination in mu...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a novel demyelination-targeting drug, could redefine MS therapy by addressing ...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal step toward a targeted therapy for multiple sclerosis, potentially offeri...
The LGL Group's participation in the Moody Capital Solutions conference highlights its strategic focus on critical technologies and disciplined capita...
Interlink Electronics' participation in the Moody Capital conference underscores its strategic growth in high-demand sensor markets and its commitment...
As small-cap life sciences and AI infrastructure sectors surge in 2026, the Moody Capital Disruptive Growth & Life Sciences Conference offers a timely...
Tonix Pharmaceuticals promotes Thomas Englese to CCO to lead commercial efforts as the company expands the launch of its fibromyalgia treatment TONMYA...
AcroMeta Group Limited has signed a non-binding term sheet to acquire a strategic stake in Macro-ATCLS Pte. Ltd., with an option for an exclusive lice...
Onco-Innovations' lead candidate ONC010 has achieved high purity in manufacturing and is progressing toward a First-in-Human study, marking a signific...
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to bolster its financial leadership and support the advancement of its B...
